PT Kalbe Farma Tbk.

Head Ofce KALBE Building Jl. Letjend. Suprapto Kav. 4, Jakarta 10510 Phone (021) 4287-3888 Fax (021) 4287-3680 Website: www.kalbe.co.id Kawasan Industri Delta Silicon Jl. M.H. Thamrin Blok A3-I Lippo Cikarang, Bekasi 17550 Phone (021) 8990-7337, 8990-7333 Fax (021) 8990-7360 Pharmaceuticals PMDN

Pharmaceuticals Summary of Financial Statement

(Million Rupiah) 2007 2008 2009
Total Assets Current Assets of which Cash and cash equivalents Time deposits Trade receivables Inventories Non-Current Assets of which Fixed Assets-Net Deffered Tax Assets-Net Investments Other Assets Liabilities Current Liabilities of which Short-term debt Trade payables Taxes payable Non-Current Liabilities Minority Interest in Subsidiaries Shareholders' Equity Paid-up capital Paid-up capital in excess of par value Revaluation of fixed assets Retained earnings (accumulated loss) Net Sales Cost of Goods Sold Gross Profit Operating Expenses Operating Profit Other Income (Expenses) Profit (Loss) before Taxes Profit (Loss) after Taxes Per Share Data (Rp) Earnings (Loss) per Share Equity per Share Dividend per Share Closing Price Financial Ratios PER (x) PBV (x) Dividend Payout (%) Dividend Yield (%) Current Ratio (x) Debt to Equity (x) Leverage Ratio (x) Gross Profit Margin (x) Operating Profit Margin (x) Net Profit Margin (x) Inventory Turnover (x) Total Assets Turnover (x) ROI (%) ROE (%) PER = 20.57x ; PBV = 4.59x (June 2010) Financial Year: December 31 Public Accountant: Purwantono, Sarwoko & Sandjaja 5,138,213 3,760,008 1,116,346 175,833 869,572 1,427,068 1,378,205 1,204,148 31,109 704 15,013 1,121,539 754,629 43,717 328,291 127,042 366,910 629,812 3,386,862 507,801 2,640 4,153 2,872,268 7,004,910 3,453,279 3,551,631 2,422,276 1,129,355 29,313 1,158,667 705,694 69 333 n.a 1,260 18.13 3.78 n.a n.a 4.98 0.33 0.22 0.51 0.16 0.10 2.42 1.36 13.73 20.84 5,703,832 4,168,055 1,321,798 124,749 935,357 1,606,124 1,535,778 1,327,347 33,064 n.a 19,757 1,359,297 1,250,372 145,889 305,568 177,901 108,925 722,137 3,622,399 507,801 2,640 n.a 3,111,958 7,877,366 4,073,726 3,803,641 2,660,928 1,142,712 35,309 1,178,022 706,822 70 357 n.a 400 5.75 1.12 n.a n.a 3.33 0.38 0.24 0.48 0.15 0.09 2.54 1.38 12.39 19.51 6,482,447 4,701,893 1,562,664 62,596 1,203,941 1,561,382 1,780,554 1,398,128 29,354 n.a 26,101 1,691,775 1,574,137 339,132 481,511 273,181 117,637 480,234 4,310,438 507,801 2,640 n.a 3,799,997 9,087,348 4,575,407 4,511,940 2,946,066 1,565,875 (94,803) 1,471,072 929,004 91 424 25 1,300 14.21 3.06 27.33 5.89 2.99 0.39 0.26 0.50 0.17 0.10 2.93 1.40 14.33 21.55

Factory

Business Company Status

Financial Performance: Net income in 2009 soared to IDR929 billion compared to IDR706 billion booked in 2008. The higher income was partly due to increase in net sales from IDR7.877 trillion to IDR9.087 trillion. Brief History: Established in 1966, PT Kalbe Farma Tbk. (the Company or Kalbe) has gone a long way from its humble beginnings as a garage-operated pharmaceutical business in North Jakarta. Throughout its more than 40-year history, the Company has expanded by strategic acquisitions of pharmaceutical companies, building a leading brand positioning and reaching to international markets to transform itself into an integrated consumer health and nutrition enterprise with unrivalled innovation, marketing, branding, distribution, nancial strength and R&D and production expertise to promote its mission to improve health for a better life. The Kalbe Group has an extensive and strong portfolio of brands in the prescription pharmaceuticals, OTC pharmaceuticals, energy drink and nutrition products, complemented with a robust packaging and distribution arm that reaches over 1 million outlets. The Company has succeeded in promoting its brands as the undisputed market leaders not only in Indonesia but also in the international markets, establishing such household names across all healthcare and pharmaceutical segments as Promag, Mixagrip, Woods, Komix, Prenagen and Extra Joss. Also, fostering and expanding alliances with international partners have accelerated Kalbes advances in international markets and sophisticated R&D ventures as well as the latest pharmaceutical and healthcare developments, including stem cell and cancer research. The Groups consolidation in 2005 has further enhanced production, marketing and nancial capabilities, providing greater leverage to widen local and international exposure. Today, Kalbe is the largest publicly-listed pharmaceutical company in Southeast Asia with over US$ 1 billion in market capitalization and revenues of over Rp 7 trillion. Its cashrich position today also provides for unlimited expansion opportunities in the future. Shareholders PT Gira Sole Prima PT Santa Seha Sanadi PT Diptanala Bahana PT Lucasta Murni Cemerlang PT Ladang Ira Panen PT Bina Artha Charisma Public 10.17% 9.62% 9.49% 9.47% 9.22% 8.69% 43.34%

(million rupiah) 2010 2009 June

Total Assets Current Assets Non-Current Assets Liabilities Shareholders' Equity Net Sales Profit after Taxes ROI (%) ROE (%) 6,876,153 5,027,924 1,848,230 1,733,413 4,649,763 4,706,810 572,337 8.32 12.31

June
6,528,633 5,010,908 1,517,725 1,856,978 3,906,121 4,217,478 398,709 6.11 10.21

414

Indonesian Capital Market Directory 2010

PT Kalbe Farma Tbk.

Board of Commissioners President Commissioner Drs. Johannes Setijono Commissioners Santoso Oen, BA, Yozef Darmawan Angkasa, Ferdinand Aryanto, Farid A. Moeloek, Wahjudi Prakarsa
No 1 2 3 4 5 6 7 8 9 10 11 12 13 Type of Listing First Issue Partial Listing Cooperative Company Listing Bonus Shares Right Issue Bonus Shares Dividend Shares Stock Split Stock Split Bonus Shares Stock Split Additional Listing (Merger) Listing Date 1991 1991 1992 1992 1992 1993 1994 1994 1996 1999 2000 2-Jan-04 21-Dec-05

Pharmaceuticals

Board of Directors President Director Bernadette Ruth Irawati Setiady Vice President Director Johanes Berchman Apik Ibrahim Directors Budi Dharma Wireksoatmodjo, Vidjongtius, Herman Widjaja Number of Employees 10,022
Trading Date 1991 1992 1999 1992 1992 1993 1994 1994 1996 1999 2000 2-Jan-04 21-Dec-05 Number of Shares per Listing 10,000,000 10,000,000 500,000 29,500,000 50,000,000 8,000,000 75,600,000 32,400,000 216,000,000 1,728,000,000 1,900,800,000 4,060,800,000 2,034,414,422 Total Listed Shares 10,000,000 20,000,000 20,500,000 50,000,000 100,000,000 108,000,000 183,600,000 216,000,000 432,000,000 2,160,000,000 4,060,800,000 8,121,600,000 10,156,014,422

Underwriters PT Ing Barings Securities, PT Merincorp Stock Price, Frequency, Trading Days, Number and Value of Shares Traded and Market Capitalization

Stock Price and Traded Chart

Stock Price (Rp) 2,500 Million Share 180 160 2,000 140 120 1,500 100 80 60 500 40 20 Jan-09 Feb-09Mar-09 Apr-09 May-09 Jun-09 Jul-09 Aug-09 Sep-09 Oct-09 Nov-09 Dec-09 Jan-10 Feb-10Mar-10 Apr-10 May-10 Jun-10 -

1,000

Institute for Economic and Financial Research

415